MatthewSaulGoldbergMD
Dermatology • New York, NYDermatopathology
Medical Director, Castle Biosciences Assistant Clinical Professor, Dermatology, The Mount Sinai Hospital
Dr. Goldberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 E 98th St
Fl 5
New York, NY 10029Phone+1 212-241-9728
Education & Training
University of Texas Southwestern Medical CenterFellowship, Dermatopathology, 2014 - 2015
University of California (San Francisco)Residency, Dermatology, 2011 - 2014
Maimonides Medical CenterInternship, Internal Medicine, 2010 - 2011
Icahn School of Medicine at Mount SinaiClass of 2010
Certifications & Licensure
CA State Medical License 2011 - 2027
AZ State Medical License 2024 - 2026
NY State Medical License 2016 - 2026
MA State Medical License 2024 - 2025
PA State Medical License 2024 - 2024
NJ State Medical License 2017 - 2021
DC State Medical License 2015 - 2018- American Board of Dermatology Dermatology
- American Board of Dermatology Dermatopathology
- Join now to see all
Publications & Presentations
PubMed
- Appropriate Statistical Methods to Assess Cross-study Diagnostic 23-Gene Expression Profile Test Performance for Cutaneous Melanocytic Neoplasms.Matthew S Goldberg, Clay J Cockerell, Jason H Rogers, Jennifer J Siegel, Brooke H Russell
The American Journal of Dermatopathology. 2024-12-01 - RE: External validation of the Melanoma Institute Australia sentinel lymph metastasis risk prediction tool using the National Cancer Database.Peter A Prieto, Matthew S Goldberg, Brian Martin
Journal of the American Academy of Dermatology. 2024-09-01 - 1 citationsDiagnostic discordance among histopathological reviewers of melanocytic lesions.Gregory A Hosler, Matthew S Goldberg, Sarah I Estrada, Brendan O'Neil, Sapna M Amin
Journal of Cutaneous Pathology. 2024-08-01
Press Mentions
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with MelanomaDecember 12th, 2024- Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant PotentialOctober 16th, 2024
- Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous MedicineMarch 8th, 2023
- Join now to see all
Professional Memberships
- Member
- American Society of DermatopathologyMember
- International Society of DermatopathologyMember
Other Languages
- Spanish, Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
